UNASSIGNED: e20521 Background: @entity2240 , which targets KIT, @entity3820 , @entity319 , has demonstrated efficacy in @entity1 with @entity677 after they experience @entity2213 failure. A study from JCO reported @entity677 @entity1 with exon 9 gene mutation or wild type had more benefit receiving @entity2240 treatment. We analysed the impact of primary and secondary gene mutation on @entity2240 treatment in Chinese @entity677 @entity1 . METHODS: We assessed the @entity5 response according to RECIST criterion in 31 @entity1 with @entity2213 -resistant/intolerant @entity677 , and examined the Kit/ @entity675 mutation status by using @entity5 specimens obtained before or after prior @entity2213 therapy. Progression-free survival (PFS) was evaluated with Kaplan-Meier methods and log-rank tests. RESULTS: Primary gene mutations examination were performed in all the @entity1 and secondary gene mutations in nine @entity1 . Primary gene mutations were identified in 77.4% @entity677 . 61.3% had exon 11 mutation, 12.9% had exon 9 mutation, 3.2% obtained exon 17 mutation, no @entity3820 gene mutation was found. 77.8% @entity1 had secondary gene mutation of the nine @entity1 and the more commonly secondary mutation were located in exon 13 and exon 17. Disease control rate with @entity2240 were observed for primary genotype: KIT exon 9 (75%),wild-type Kit/ @entity675 (57%) and Kit exon11(53%). The @entity1 with exon 9 mutation had more longer PFS (60 weeks, vs. wild type 21 weeks, p=0.022; vs. exon 11 mutation 29 weeks, p=0.070). Two @entity1 with secondary Kit exon 13 mutation and one @entity1 without secondary mutation had PR or SD, but those @entity1 with primary or secondary Kit exon 17 muations showed no clinical benefit. CONCLUSIONS: @entity677 @entity1 with KIT exon 9 mutation response well to @entity2240 treatment; @entity677 with KIT exon 17 mutation is @entity2240 -resistant.

Correlation of kinase genotypes and activity of @entity2240 in XXXX failure gastrointestinal stromal tumor.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity675 :: ('5156', 'Gene') :: ['PDGFRA'] @entity677 :: ('MESH:C564650', 'Disease') :: ['GIST'] @entity2240 :: ('MESH:C473478', 'Chemical') :: ['Sunitinib', 'sunitinib'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity319 :: ('3791', 'Gene') :: ['VEGFR'] @entity3820 :: ('5159', 'Gene') :: ['PDGFR'] @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib']
@entity2213 :: (MESH:C097613,Chemical) :: ['imatinib']
